| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected but not Quantified |
|---|
| Creation Date | 2021-09-11 23:43:16 UTC |
|---|
| Update Date | 2021-09-26 23:18:08 UTC |
|---|
| HMDB ID | HMDB0260171 |
|---|
| Secondary Accession Numbers | None |
|---|
| Metabolite Identification |
|---|
| Common Name | (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one |
|---|
| Description | (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone. Based on a literature review very few articles have been published on (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one. This compound has been identified in human blood as reported by (PMID: 31557052 ). (8r,9r,10s,13s,17r)-11,17-dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
|---|
| Structure | CC1=CC(=O)C=C2CCC3C4CCC(O)(C(=O)CO)C4(C)CC(O)C3C12C InChI=1S/C22H30O5/c1-12-8-14(24)9-13-4-5-15-16-6-7-22(27,18(26)11-23)20(16,2)10-17(25)19(15)21(12,13)3/h8-9,15-17,19,23,25,27H,4-7,10-11H2,1-3H3 |
|---|
| Synonyms | Not Available |
|---|
| Chemical Formula | C22H30O5 |
|---|
| Average Molecular Weight | 374.477 |
|---|
| Monoisotopic Molecular Weight | 374.209324066 |
|---|
| IUPAC Name | 14,17-dihydroxy-14-(2-hydroxyacetyl)-2,3,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one |
|---|
| Traditional Name | 14,17-dihydroxy-14-(2-hydroxyacetyl)-2,3,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CC1=CC(=O)C=C2CCC3C4CCC(O)(C(=O)CO)C4(C)CC(O)C3C12C |
|---|
| InChI Identifier | InChI=1S/C22H30O5/c1-12-8-14(24)9-13-4-5-15-16-6-7-22(27,18(26)11-23)20(16,2)10-17(25)19(15)21(12,13)3/h8-9,15-17,19,23,25,27H,4-7,10-11H2,1-3H3 |
|---|
| InChI Key | VVNDBKDEDMTMHN-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Steroids and steroid derivatives |
|---|
| Sub Class | Hydroxysteroids |
|---|
| Direct Parent | 21-hydroxysteroids |
|---|
| Alternative Parents | |
|---|
| Substituents | - Progestogin-skeleton
- 21-hydroxysteroid
- 20-oxosteroid
- Pregnane-skeleton
- 3-oxo-delta-1,4-steroid
- 3-oxosteroid
- Oxosteroid
- 11-hydroxysteroid
- 17-hydroxysteroid
- Delta-1,4-steroid
- Cyclic alcohol
- Tertiary alcohol
- Alpha-hydroxy ketone
- Ketone
- Secondary alcohol
- Cyclic ketone
- Primary alcohol
- Alcohol
- Hydrocarbon derivative
- Organooxygen compound
- Organic oxide
- Organic oxygen compound
- Carbonyl group
- Aliphatic homopolycyclic compound
|
|---|
| Molecular Framework | Aliphatic homopolycyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. | 5.14 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 11.9738 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.31 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2474.0 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 191.3 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 167.8 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 164.2 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 128.3 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 509.0 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 521.2 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 99.4 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 942.5 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 426.4 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1408.4 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 299.2 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 399.7 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 283.1 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 195.4 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 45.4 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatized| Metabolite | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one | CC1=CC(=O)C=C2CCC3C4CCC(O)(C(=O)CO)C4(C)CC(O)C3C12C | 3878.0 | Standard polar | 33892256 | | (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one | CC1=CC(=O)C=C2CCC3C4CCC(O)(C(=O)CO)C4(C)CC(O)C3C12C | 2764.8 | Standard non polar | 33892256 | | (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one | CC1=CC(=O)C=C2CCC3C4CCC(O)(C(=O)CO)C4(C)CC(O)C3C12C | 3368.2 | Semi standard non polar | 33892256 |
Derivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one,4TMS,isomer #1 | CC1=CC(=O)C=C2CCC3C(C(O[Si](C)(C)C)CC4(C)C3CCC4(O[Si](C)(C)C)C(=CO[Si](C)(C)C)O[Si](C)(C)C)C12C | 3302.8 | Semi standard non polar | 33892256 | | (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one,4TMS,isomer #1 | CC1=CC(=O)C=C2CCC3C(C(O[Si](C)(C)C)CC4(C)C3CCC4(O[Si](C)(C)C)C(=CO[Si](C)(C)C)O[Si](C)(C)C)C12C | 3306.6 | Standard non polar | 33892256 | | (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one,4TMS,isomer #1 | CC1=CC(=O)C=C2CCC3C(C(O[Si](C)(C)C)CC4(C)C3CCC4(O[Si](C)(C)C)C(=CO[Si](C)(C)C)O[Si](C)(C)C)C12C | 3522.5 | Standard polar | 33892256 | | (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one,4TBDMS,isomer #1 | CC1=CC(=O)C=C2CCC3C(C(O[Si](C)(C)C(C)(C)C)CC4(C)C3CCC4(O[Si](C)(C)C(C)(C)C)C(=CO[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)C12C | 4246.1 | Semi standard non polar | 33892256 | | (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one,4TBDMS,isomer #1 | CC1=CC(=O)C=C2CCC3C(C(O[Si](C)(C)C(C)(C)C)CC4(C)C3CCC4(O[Si](C)(C)C(C)(C)C)C(=CO[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)C12C | 4179.2 | Standard non polar | 33892256 | | (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one,4TBDMS,isomer #1 | CC1=CC(=O)C=C2CCC3C(C(O[Si](C)(C)C(C)(C)C)CC4(C)C3CCC4(O[Si](C)(C)C(C)(C)C)C(=CO[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)C12C | 3795.4 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (Non-derivatized) - 70eV, Positive | splash10-05o3-4977000000-abd6f9c79968ec1fe2ab | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (TMS_1_4) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (TMS_2_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (TMS_2_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (TMS_2_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (TMS_2_4) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (TMS_2_5) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (TMS_2_6) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (TMS_3_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (TMS_3_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (TMS_3_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (TMS_3_4) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (TBDMS_1_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (TBDMS_1_4) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (TBDMS_2_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (TBDMS_2_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (TBDMS_2_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (TBDMS_2_4) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (8R,9R,10S,13S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one GC-MS (TBDMS_2_5) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum |
|
|---|